Endonovo Therapeutics, Inc.
Endonovo Therapeutics, Inc.
Your view on ENDV
Overview
What the company does, where it operates, and who runs it.
About Endonovo Therapeutics, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alan Brian Collier
- Headquarters
- 6320 Canoga Avenue, Woodland Hills, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alan Brian Collier
- Headquarters
- 6320 Canoga Avenue, Woodland Hills, CA, US
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema.
Its Electroceuticals medical device is also used for the treatment of inflammation, wounds, cardiovascular diseases, chronic kidney diseases, liver diseases, non-alcoholic steatohepatitis, peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis.
Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Endonovo Therapeutics, Inc., and the rating behind it. ENDV last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Endonovo Therapeutics, Inc.. Starting points for Endonovo Therapeutics, Inc.: beta -1.36 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Endonovo Therapeutics, Inc.. Endonovo Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Endonovo Therapeutics, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Endonovo Therapeutics, Inc.. Endonovo Therapeutics, Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Endonovo Therapeutics, Inc. valued side by side against its closest peers. Endonovo Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Endonovo Therapeutics, Inc., and how their positions are changing. At a $31,875 market value, institutional positions materially move Endonovo Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Endonovo Therapeutics, Inc. executives and directors. Shares of Endonovo Therapeutics, Inc. have traded between $0.0001 and $0.0003 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Endonovo Therapeutics, Inc.. Endonovo Therapeutics, Inc. is a $31,875 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Endonovo Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Endonovo Therapeutics, Inc.. Coverage tracks Endonovo Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.